- Gyre Therapeutics announced its quarterly earnings results, reporting an EPS of ($0.12) which missed the consensus estimate of ($0.08) alongside revenue of $29.11 million.
- The company experienced various insider transactions and adjustments in holdings by institutional investors such as Bank of America Corp DE and JPMorgan Chase & Co. during the period.
- Shares traded up 4.2% to $6.67 following the financial disclosure, amidst fluctuating analyst ratings and market performance data.
